Human hepatocellular carcinoma: Expression profiles-based molecular interpretations and clinical applications

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 96-102

  Hui, Kam M ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Affymetrix microarrays; cDNA spotted DNA microarray; Differential gene expression profiling; HBV; HCV; Hepatocarcinogenesis; Hepatocellular carcinoma (HCC); HSV 1 amplicon vector; Iron homeostasis; Liver specific uncoupling protein; Prediction of recurrence; Suppression subtractive hybridization

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARRIER PROTEIN; CAVEOLIN 2; CYCLIN A2; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DNA; GELATINASE B; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEPCIDIN; I KAPPA B; IRON; MACROPHAGE ELASTASE; MYC PROTEIN; N ACETYLGLUCOSAMINE 6 SULFATASE; NUCLEAR FACTOR Y; OSTEOPONTIN; PROTEIN C JUN; PROTEIN P53; PROTEIN SH3; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RGS PROTEIN; STAT1 PROTEIN; STROMELYSIN 3; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VIRUS VECTOR; WNT PROTEIN;

CANCER GENE THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LIVER DISEASE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; LIVER TRANSPLANTATION; METASTASIS POTENTIAL; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SUBTRACTIVE HYBRIDIZATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; WORKSHOP;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 1;

EID: 70350569443     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.005     Document Type: Review

References (46)

1. Kirk G.D., Bah E., and Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 27 (2006) 2070-2082
2. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6 (2006) 674-687
3. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 25 (2006) 3778-3786
4. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
5. Schafer D.F., and Sorrell M.F. Hepatocellular carcinoma. Lancet 353 (1999) 1253-1257
6. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8 (2002) 816-824
7. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
8. Bosch F.X., Ribes J., Cleries R., and Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9 (2005) 191-211
9. Kane M.A. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 2-3
10. Mann D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., and Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 43 (2007) 979-992
11. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
12. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356 (2007) 11-20
13. Wang S., Ooi L., and Hui K.M. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin. Cancer Res. 13 (2007) 6275-6283
14. Del Rio M., Molina F., Bascoul-Mollevi C., Copois V., Bibeau F., Chalbos P., et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25 (2007) 773-780
15. Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 20 (2006) 1839-1845
16. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26 (2007) 3629-3636
17. Tan M., Ooi L.L., Aw S.E., and Hui K.M. Cloning and identification of hepatocellular carcinoma down-regulated mitochondrial carrier protein, a novel liver-specific uncoupling protein. J. Biol. Chem. 279 (2004) 45235-45244
18. Liu B.H., Goh C., Ooi L.L., and Hui K.M. Identification of unique and common low abundance tumor-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis. Oncogene 27 (2008) 4128-4136
19. Tommasi S., Pinto R., Pilato B., and Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr. Pharm. Des. 13 (2007) 3279-3287
20. Chattopadhyay D., Manas D.M., and Reeves H.L. The development of targeted therapies for hepatocellular cancer. Curr. Pharm. Des. 13 (2007) 3292-3300
21. Arsura M., and Cavin L.G. Nuclear factor-kB and liver carcinogenesis. Cancer Lett. 229 (2005) 157-169
22. Gao Z.H., Tretiakova M.S., Liu W.H., Gong C., Farris P.D., and Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod. Pathol. 19 (2006) 533-540
23. Eichhorst S.T. Modulation of apoptosis as a target for liver disease. Expert Opin. Ther. Targets 9 (2005) 83-99
24. Hui K.M. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr. Opin. Mol. Ther. 9 (2007) 378-384
25. Sena-Esteves M., Saeki Y., Fraefel C., and Breakefield X.O. HSV-1 amplicon vectors-simplicity and versatility. Mol. Ther. 2 (2000) 9-15
26. Nettelbeck D.M., Jérôme V., and Müller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 16 (2000) 174-181
27. Michalopoulos G.K. Liver regeneration. Cell. Physiol. 213 (2007) 286-300
28. Wang G.Y., Ho I.A., Sia K.C., Miao L., Hui K.M., and Lam P.Y. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther. 18 (2007) 222-231
29. Lam Y.P., Sia K.C., Khong J.K., Geest B.D., Lim K.S., Ho I.A., Wang G.Y., Miao L., Huynh H., and Hui K.M. An efficient and safe Herpes Simplex Virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol. Ther. 15 (2007) 1129-1136
30. Comijin J., Berx G., Vermassen P., Verschueren K., Grunsven L., Bruyneel E., et al. The two handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasions. Mol. Cell 7 (2001) 1267-1278
31. Tsopanomichalou M., Kouroumalis E., Ergazaki M., and Spandidos D.A. Loss of heterozygosity and microsatellite instability in human non-neoplastic hepatic lesions. Liver 19 (1999) 305-311
32. Odom D.T., Zizlsperger N., Gordon D.B., Bell G.W., Rinaldi N.J., Murray H.L., et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 303 (2004) 1378-1381
33. Kirk G.D., Lesi O.A., Mendy M., Szymanska K., Whittle H., Goedert J.J., et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24 (2005) 5858-5867
34. Shiota G., Kishimoto Y., Suyama A., Okubo M., Katayama S., Harada K., et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J. Hepatol. 27 (1997) 661-668
35. Ramm G.A., and Ruddell R.G. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin. Liver Dis. 25 (2005) 433-449
36. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127 (2004) S79-S86
37. Pessayre D., Berson A., Fromenty B., and Mansouri A. Mitochondria in steatohepatitis. Semin. Liver Dis. 21 (2001) 57-69
38. Klingenberg M. Uncoupling proteins-how do they work and how are they regulated. IUBMB Life 32 (2000) 89-90
39. Ramsey J.J., Harper M.E., and Weindruch R. Restriction of energy intake, energy expenditure, and aging. Free Radic. Biol. Med. 29 (2000) 946-968
40. Mitchell P., and Moyle J. Evidence discriminating between the chemical and the chemiosmotic mechanisms of electron transport phosphorylation. Nature 208 (1965) 1205-1206
41. Modica-Napolitano J.S., Kulawiec M., and Singh K.K. Mitochondria and human cancer. Curr. Mol. Med. 7 (2007) 121-131
42. Modica-Napolitano J.S., and Aprille J.R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 49 (2001) 63-70
43. Morgan J., and Oseroff A.R. Mitochondria-based photodynamic anti-cancer therapy. Adv. Drug Deliv. Rev. 49 (2001) 71-86
44. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol. 23 (2005) 8093-8108
45. Katoh H., Ojima H., Kokubu A., Saito S., Kondo T., Kosuge T., et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 133 (2007) 1475-1486
46. Boyault S., Rickman D.S., de Reyniès A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52